Recursion to Participate in Upcoming Investor Conferences
02 Maio 2023 - 9:30AM
Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading
the space by decoding biology to industrialize drug discovery,
today announced its participation in the following investor
conferences:
- Bank of America Securities 2023 Health Care
Conference – May 9 through May 11, 2023
- 18th Annual Needham Technology & Media
Conference – May 16 through May 18, 2023
- Morgan Stanley Sustainable Finance Summit –
May 22 through May 25, 2023
About RecursionRecursion is a clinical stage
TechBio company leading the space by decoding biology to
industrialize drug discovery. Enabling its mission is the Recursion
OS, a platform built across diverse technologies that continuously
expands one of the world’s largest proprietary biological and
chemical datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology and chemistry to advance the future of
medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, those
regarding early and late stage discovery, preclinical, and clinical
programs; licenses and collaborations; prospective products and
their potential future indications and market opportunities;
Recursion OS and other technologies; business and financial plans
and performance; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as “plan,” “will,” “expect,” “anticipate,”
“intend,” “believe,” “potential,” “continue,” and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K. All
forward-looking statements are based on management’s current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024